Litcius/Paper detail

Effect of vitamin D supplementation on depression in older Australian adults

Sabbir Tahmidur Rahman, Mary Waterhouse, Briony Duarte Romero, Catherine Baxter, Dallas R. English, Osvaldo P. Almeida, Michael Berk, Peter R. Ebeling, Bruce K. Armstrong, Donald S.A. McLeod, Günter Härtel, Rachel O’Connell, Hai Pham, James G. Scott, Jolieke C. van der Pols, Alison Venn, Penelope M. Webb, David C. Whiteman, Rachel Ε. Neale

2022International Journal of Geriatric Psychiatry13 citationsDOIOpen Access PDF

Abstract

OBJECTIVES: To investigate whether vitamin D supplementation reduces depressive symptoms and incidence of antidepressant use. METHODS: for the prevention of all-cause mortality. Participants were Australians aged 60-84 years. Participants completed the Patient Health Questionnaire (PHQ-9) at 1, 2 and 5 years after randomization to measure depressive symptoms; national prescribing records were used to capture antidepressant use. We used mixed models and survival models. RESULTS: Analyses of PHQ-9 scores included 20,487 participants (mean age 69·3 years, 46% women); the mean difference (MD) in PHQ-9 score (vitamin D vs. placebo) was 0·02 (95% CI -0·06, 0·11). There was negligible difference in the prevalence of clinically relevant depression (PHQ-9 score ≥10) (odds ratio 0·99; 95% CI 0·90, 1·08). We included 16,670 participants in the analyses of incident antidepressant use (mean age 69·4 years, 43% women). Incidence of antidepressant use was similar between the groups (hazard ratio [HR] 1·04; 95% CI 0·96, 1·12). In subgroup analyses, vitamin D improved PHQ-9 scores in those taking antidepressants at baseline (MD -0·25; 95% CI -0·49, -0·01; p-interaction = 0·02). It decreased risk of antidepressant use in participants with predicted 25(OH)D concentration <50 nmol/L (HR 0·88; 95% CI 0·75, 1·02; p-interaction = 0·01) and increased risk in those with predicted 25(OH)D ≥ 50 nmol/L (HR 1·10; 95% CI 1·01, 1·20). CONCLUSION: was not of benefit for measures of depression overall, but there was some evidence of benefit in subgroup analyses. CLINICAL TRIAL REGISTRATION: The trial is registered on the Australian New Zealand Clinical Trials Registry: ACTRN12613000743763. https://www.anzctr.org.au/.

Topics & Concepts

MedicinePlaceboHazard ratioPatient Health QuestionnaireInternal medicineOdds ratioDepression (economics)Incidence (geometry)Vitamin D and neurologyAntidepressantRandomizationRandomized controlled trialMajor depressive disorderConfidence intervalDepressive symptomsPsychiatryAnxietyAlternative medicineOpticsHippocampusMacroeconomicsPhysicsEconomicsPathologyAmygdalaVitamin D Research StudiesTryptophan and brain disordersVitamin C and Antioxidants Research